Fulcrum Therapeutics, Inc.
FULC· Nasdaq
Filed Mar 5, 2020 · 10-K · 65 days after period end · 0001564590-20-008951
derived · Computed from the longer spans the company filed.
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|
| Net Income | -$16.12M | -$8.86M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
ended Dec 31, 2019 · filed Mar 5, 2020 · 65 d after period end